undamentalytics Newsletter
Sign in

Century Therapeutics, Inc. income statement

In fiscal 2025, Century Therapeutics, Inc. reported revenue of $109m, up 1556.8% on the year before, operating income of −$17.3m (a -15.8% margin) and net income of −$9.6m, or −$0.14 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2022Dec 20222023Dec 20232024Dec 20242025Dec 2025
Revenue527109
Research and development979310796
General and administrative32353324
Operating income−134−147−138−17
Interest expense11——
Income before tax−131−135−125−10
Income tax022−0
Net income−131−137−127−10
Diluted EPS−$2.96−$2.30−$1.61−$0.14
Diluted shares (average)32m59m79m87m
EBITDA−125−134−125−4

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: IPSC vs XNCRIPSC vs KYMRIPSC vs SPRY

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Century Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Century Therapeutics, Inc.